Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Jasper Therapeutics Inc. (JSPR)

Jasper Therapeutics Inc. (JSPR)
4.50 x 2 4.90 x 69
Post-market by (Cboe BZX)
4.73 -0.16 (-3.27%) 04/25/25 [NASDAQ]
4.50 x 2 4.90 x 69
Post-market 4.84 +0.11 (+2.33%) 19:03 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.61
Day High
4.89
Open 4.85
Previous Close 4.89 4.89
Volume 104,400 104,400
Avg Vol 181,155 181,155
Stochastic %K 87.15% 87.15%
Weighted Alpha -59.19 -59.19
5-Day Change +0.76 (+19.14%) +0.76 (+19.14%)
52-Week Range 3.13 - 26.83 3.13 - 26.83
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,458
  • Shares Outstanding, K 15,022
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,270 K
  • EBIT $ -76 M
  • EBITDA $ -75 M
  • 60-Month Beta 2.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.11

Options Overview Details

View History
  • Implied Volatility 136.79% ( -7.01%)
  • Historical Volatility 80.99%
  • IV Percentile 57%
  • IV Rank 22.54%
  • IV High 435.70% on 04/09/25
  • IV Low 49.82% on 10/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 46
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 1,215
  • Open Int (30-Day) 1,457

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.17
  • Number of Estimates 3
  • High Estimate -0.69
  • Low Estimate -1.51
  • Prior Year -1.03
  • Growth Rate Est. (year over year) -13.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.13 +51.12%
on 04/09/25
Period Open: 4.99
5.09 -6.98%
on 03/26/25
-0.26 (-5.21%)
since 03/25/25
3-Month
3.13 +51.12%
on 04/09/25
Period Open: 5.70
7.06 -33.00%
on 02/06/25
-0.97 (-17.02%)
since 01/24/25
52-Week
3.13 +51.12%
on 04/09/25
Period Open: 21.18
26.83 -82.37%
on 06/06/24
-16.45 (-77.67%)
since 04/25/24

Most Recent Stories

More News
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

JSPR : 4.73 (-3.27%)
Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

JSPR : 4.73 (-3.27%)
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

JSPR : 4.73 (-3.27%)
Jasper Therapeutics to Present at Upcoming March Investor Conferences

JSPR : 4.73 (-3.27%)
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

JSPR : 4.73 (-3.27%)
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

JSPR : 4.73 (-3.27%)
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

JSPR : 4.73 (-3.27%)
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

JSPR : 4.73 (-3.27%)
Insider Sale: Chief Operating Officer of $JSPR (JSPR) Sells 900 Shares

Jeetinder Singh Mahal, the Chief Operating Officer of $JSPR ($JSPR), sold 900 shares of the company on 12-12-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

JSPR : 4.73 (-3.27%)
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab for Allergic Asthma

Jasper Therapeutics initiates Phase 1b/2a study of briquilimab for allergic asthma, targeting mast cell-driven diseases.Quiver AI SummaryJasper Therapeutics, Inc. has announced the dosing of the first...

JSPR : 4.73 (-3.27%)

Business Summary

Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 5.15
2nd Resistance Point 5.02
1st Resistance Point 4.88
Last Price 4.73
1st Support Level 4.60
2nd Support Level 4.47
3rd Support Level 4.32

See More

52-Week High 26.83
Fibonacci 61.8% 17.78
Fibonacci 50% 14.98
Fibonacci 38.2% 12.19
Last Price 4.73
52-Week Low 3.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective